SCHEMBL7066464

SCHEMBL7066464

O=C(O)C1(NS(=O)(=O)c2cccc([N+](=O)[O-])c2)CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.57
USP2 O75604 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CA2 P00918 2/20 0.56
MMP2 P08253 2/20 0.56
CA1 P00915 1/20 0.56
MMP1 P03956 1/20 0.56
MMP9 P14780 1/20 0.56
MMP8 P22894 1/20 0.56
MMP13 P45452 1/20 0.56
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
F2 P00734 2/20 0.49
PRSS1 P07477 2/20 0.49
PRSS2 P07478 2/20 0.49
PRSS3 P35030 2/20 0.49
DDX3X O00571 1/20 0.48
CA12 O43570 1/20 0.48
CA9 Q16790 1/20 0.48
ALDH1A1 P00352 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14676583 0.96 CA2 (0.57) HTTUSP2SMN1; SMN2CA2MMP2
SCHEMBL5674730 0.86 SMN1; SMN2 (0.56) HTTUSP2SMN1; SMN2CA2MMP2
SCHEMBL14677368 0.82 CA2 (0.51) HTTUSP2SMN1; SMN2CA2MMP2
SCHEMBL5675304 0.80 USP2 (0.60) HTTUSP2SMN1; SMN2CA2MMP2
SCHEMBL14676227 0.78 USP2 (0.58) HTTUSP2SMN1; SMN2CA2MMP2
SCHEMBL15892101 0.77 L3MBTL1 (0.54) HTTSMN1; SMN2CA2MMP2CA1
SCHEMBL7064055 0.77 USP2 (0.62) HTTUSP2SMN1; SMN2MMP1MMP13
SCHEMBL6990928 0.77 USP2 (0.55) HTTUSP2SMN1; SMN2ALDH1A1PLG
SCHEMBL7066513 0.77 USP2 (0.58) HTTUSP2SMN1; SMN2CA2MMP2
SCHEMBL14678136 0.77 HSD11B1 (0.53) CA2MMP2CA1MMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP claimed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 HTT 1221/4885USP2 1089/4885SMN1; SMN2 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.